Drugs.com - Clinical Trials

Cellenkos Announces US FDA Orphan Drug Designation Granted to CK0801 (Allogeneic Cord Blood derived T regulatory Cell Product) for Treatment of Aplastic Anemia

HOUSTON, April 14, 2025 /PRNewswire/ -- Cellenkos Inc., a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf, T regulatory (Treg) cell therapies for inflammatory disease areas of high unmet needs and autoimmune...

Apr 17, 2025 - 04:34
 0
Cellenkos Announces US FDA Orphan Drug Designation Granted to CK0801 (Allogeneic Cord Blood derived T regulatory Cell Product) for Treatment of Aplastic Anemia
HOUSTON, April 14, 2025 /PRNewswire/ -- Cellenkos Inc., a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf, T regulatory (Treg) cell therapies for inflammatory disease areas of high unmet needs and autoimmune...
Read More

Tags:

Previous Article

Unicard secures partial certification for ITSO 2.1.5 transport solutions

Next Article

When gold is this hot, most sovereign risk considerations slide away

Related Posts

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Mersana Therapeutics Announces Additional FDA Fast Trac...

Feb 9, 2025  0

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Eledon Pharmaceuticals Announces Use of Tegoprubart as ...

Feb 9, 2025  0

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Pyxis Oncology Granted FDA Fast Track Designation for P...

Feb 27, 2025  0